Bruno Cenni

2.9k total citations · 1 hit paper
35 papers, 2.4k citations indexed

About

Bruno Cenni is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Bruno Cenni has authored 35 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Genetics and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Bruno Cenni's work include Chronic Lymphocytic Leukemia Research (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Estrogen and related hormone effects (5 papers). Bruno Cenni is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Estrogen and related hormone effects (5 papers). Bruno Cenni collaborates with scholars based in Switzerland, United States and Finland. Bruno Cenni's co-authors include Didier Picard, Stefan Aebi, R D Christen, Daniel Fink, A Nehmé, S Nebel, S B Howell, Hua Zheng, Stephen B. Howell and Marcello Maggiolini and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Genes & Development.

In The Last Decade

Bruno Cenni

35 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The role of DNA mismatch repair in platinum drug resistance.

1996 512 citations Daniel Fink, Stefan Aebi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bruno Cenni Switzerland	22	1.1k	804	751	388	374	35	2.4k
Jean‐Michel Flaman France	26	1.5k 1.3×	250 0.3×	1.1k 1.4×	334 0.9×	537 1.4×	53	2.7k
Hae Yong Yoo South Korea	24	1.7k 1.5×	517 0.6×	964 1.3×	105 0.3×	381 1.0×	46	2.5k
J G Shelton United States	11	1.6k 1.4×	257 0.3×	593 0.8×	116 0.3×	368 1.0×	11	2.4k
Olga Chernova United States	27	2.2k 1.9×	227 0.3×	1.1k 1.5×	314 0.8×	565 1.5×	42	3.7k
Liya Gu United States	33	2.5k 2.2×	1.0k 1.3×	379 0.5×	230 0.6×	700 1.9×	67	3.1k
Kathryn Balmanno United Kingdom	25	2.4k 2.1×	429 0.5×	956 1.3×	94 0.2×	375 1.0×	45	3.2k
Olivier Coqueret France	31	2.1k 1.9×	269 0.3×	1.4k 1.9×	219 0.6×	565 1.5×	69	3.4k
Gabriel Pons Spain	23	1.3k 1.2×	261 0.3×	427 0.6×	114 0.3×	250 0.7×	60	2.1k
Akiko Kimura Japan	26	1.4k 1.2×	175 0.2×	545 0.7×	252 0.6×	366 1.0×	49	2.4k
Lucia Magnelli Italy	27	1.4k 1.2×	163 0.2×	612 0.8×	344 0.9×	647 1.7×	83	2.7k

Countries citing papers authored by Bruno Cenni

Since Specialization

Citations

This map shows the geographic impact of Bruno Cenni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Cenni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Cenni more than expected).

Fields of papers citing papers by Bruno Cenni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Cenni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Cenni. The network helps show where Bruno Cenni may publish in the future.

Co-authorship network of co-authors of Bruno Cenni

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Cenni. A scholar is included among the top collaborators of Bruno Cenni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Cenni. Bruno Cenni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pulz, Robert, Daniela Angst, & Bruno Cenni. (2025). Next generation Bruton's tyrosine kinase inhibitors – characterization of in vitro potency and selectivity. European Journal of Pharmacology. 1002. 177747–177747. 1 indexed citations

Gimeno, Ramón, et al.. (2023). Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response. Clinical and Translational Allergy. 13(3). e12227–e12227. 18 indexed citations

Dörner, Thomas, Martin Kaul, Antónia Szántó, et al.. (2023). Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren’s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Annals of the Rheumatic Diseases. 83(3). 360–371. 22 indexed citations

Nuesslein‐Hildesheim, Barbara, Enrico Ferrero, Catherine Huck, et al.. (2023). Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. Journal of Neuroinflammation. 20(1). 194–194. 9 indexed citations

Pulz, Robert, et al.. (2023). Remibrutinib, a Novel Bruton Tyrosine Kinase Inhibitor, Exhibits Improved Target Selectivity and Potency in Vitro. Multiple Sclerosis and Related Disorders. 80. 105313–105313. 1 indexed citations

Kaul, Martin, Peter End, Maciej Cabanski, et al.. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clinical and Translational Science. 14(5). 1756–1768. 59 indexed citations

Pulz, Robert, Daniela Angst, Janet Dawson, et al.. (2019). Design of Potent and Selective Covalent Inhibitors of Bruton’s Tyrosine Kinase Targeting an Inactive Conformation. ACS Medicinal Chemistry Letters. 10(10). 1467–1472. 16 indexed citations

Dudek, Peter, et al.. (2010). CARM1 mediates the ligand-independent and tamoxifen-resistant activation of the estrogen receptor α by cAMP. Genes & Development. 24(7). 708–719. 82 indexed citations

Gottar, Marie, et al.. (2008). The Lysosomal Transmembrane Protein 9B Regulates the Activity of Inflammatory Signaling Pathways. Journal of Biological Chemistry. 283(31). 21487–21494. 44 indexed citations

10.

Fouladkou, Fatemeh, Pierre Fustier, Bruno Cenni, et al.. (2007). Identification of polymorphisms in the human 11beta‐hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. The FASEB Journal. 21(13). 3618–3628. 41 indexed citations

11.

Azevedo, Luı́sa, Laura Vilarinho, Elisa Leão Teles, et al.. (2006). Mutational Spectrum and Linkage Disequilibrium Patterns at the Ornithine Transcarbamylase Gene (OTC). Annals of Human Genetics. 70(6). 797–801. 5 indexed citations

12.

Busso, Nathalie, Roland Feifel, Bruno Cenni, et al.. (2006). Evaluation of protease‐activated receptor 2 in murine models of arthritis. Arthritis & Rheumatism. 56(1). 101–107. 55 indexed citations

13.

Leupin, Nicolas, Bruno Cenni, Urban Novak, et al.. (2003). Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL). British Journal of Haematology. 121(1). 97–100. 37 indexed citations

14.

Thormann, Wolfgang, Ira S. Lurie, Bruce McCord, et al.. (2001). Advances of capillary electrophoresis in clinical and forensic analysis (1999-2000). Electrophoresis. 22(19). 4216–4243. 77 indexed citations

15.

Maggiolini, Marcello, Daniela Bonofiglio, Stefania Marsico, et al.. (2001). Estrogen Receptor α Mediates the Proliferative but Not the Cytotoxic Dose-Dependent Effects of Two Major Phytoestrogens on Human Breast Cancer Cells. Molecular Pharmacology. 60(3). 595–602. 97 indexed citations

16.

Cenni, Bruno, Stefan Aebi, A Nehmé, & R D Christen. (2001). Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. Cancer Chemotherapy and Pharmacology. 47(5). 397–403. 15 indexed citations

17.

Cenni, Bruno, Harry K.W. Kim, Glenn J. Bubley, et al.. (1999). Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin. British Journal of Cancer. 80(5-6). 699–704. 12 indexed citations

18.

Cenni, Bruno & Didier Picard. (1999). Two Compounds Commonly Used for Phospholipase C Inhibition Activate the Nuclear Estrogen Receptors. Biochemical and Biophysical Research Communications. 261(2). 340–344. 19 indexed citations

19.

Cenni, Bruno & Bruno Betschart. (1995). The in vitro Distribution of Halofantrine in Human Blood and <i>Plasmodium falciparum</i><i>-</i>Parasitised Red Blood Cells. Chemotherapy. 41(3). 153–158. 8 indexed citations

20.

Cenni, Bruno, et al.. (1995). The antimalarial drug halofantrine is bound mainly to low and high density lipoproteins in human serum.. British Journal of Clinical Pharmacology. 39(5). 519–526. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact